Long term effectiveness of uterine sparing fibroid treatments - the lifetime cumulative incidence of uterine leiomyomas (fibroids or UF) is >80% among black women and ~70% in white women
Active Project Grant Awarded Last action
- Award ID
- R01HD109127
- Recipient
-
Henry Ford Health System UEI R9NXPE2GTCN9
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,274,781
Award facts
- Assistance listing
- 93.865 Child Health and Human Development Extramural Research
- Completion date 79% complete
- Place of performance
- Detroit, MI 48202, USA
Award details come from USAspending.gov.
Description
UF are the most common reason for hysterectomy in the U.S. And can cause heavy menstrual bleeding requiring blood transfusion(S), pelvic pain, urinary and bowel problems, infertility, and substantial impairment of quality of life (QOL). While alternatives to hysterectomy are available including myomectomy (fibroid removal), uterine artery embolization (UAE), endometrial ablation (EA), and radiofrequency ablation (RFA), there are significant knowledge gaps that preclude the development of evidence-based clinical guidelines to select an appropriate UF treatment. Prior studies of UF treatments have several key deficits including limited follow-up time (40% black) population, and include detailed imaging information (UF size, number and location), and self-reported desire for future fertility obtained prior to the index fibroid treatment. Among women who have undergone one of four uterine-sparing procedures (myomectomy, EA, UAE and RFA), validated questionnaires from pre-procedure will be repeated annually up to 10 years post-procedure, to achieve the following: aim 1: compare changes in fibroid symptoms and quality of life from pre-procedure up to 10 years post-procedure among four uterine-sparing procedures: myomectomy, EA, UAE, and RFA. Aim 2: compare the rate of and time until treatment failure up to 10 years after the index treatment among participants who had myomectomy, EA, UAE, and RFA. Aim 3: identify baseline factors that predict clinical effectiveness after myomectomy, EA, UAE, and RFA and with patient and provider input, create a clinical prediction tool (fibroid treatment calculator) that supports informed decision-making. Our preliminary data demonstrate ongoing active engagement of these participants. This project is a time-limited opportunity that uses two well-designed longitudinal cohorts with comprehensive baseline information collected with validated questionnaires and will yield results for immediate application in clinical care.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $597,502 | |
| Amendment | $600,362 | |
| Amendment | $592,123 | |
| Original award | $484,794 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The George Washington University | $20,255 | |
| Subrecipient not on record | $71,410 | |
| University Of North Carolina At Chapel Hill | $90,677 | |
| Subrecipient not on record | $171,464 |
Quick answers
Who received award R01HD109127?
R01HD109127 was awarded to Henry Ford Health System by National Institute of Child Health and Human Development (National Institutes of Health) on September 1, 2023.
How much is award R01HD109127 worth?
$2,274,781 has been obligated on R01HD109127.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award